Study Supports Changing Classification of Renal Cell Carcinoma Study Supports Changing Classification of Renal Cell Carcinoma
The definition of stage 4 renal cell carcinoma should be expanded to include lymph node-positive stage 3 disease, according to a new study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Certain pesticides linked to kidney cancer in agricultural workers
New findings from the Agricultural Health Study suggest exposure to certain pesticides may increase risk of renal cell carcinoma. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news

Liquid Biopsy Promising in Spotting Kidney Cancer Liquid Biopsy Promising in Spotting Kidney Cancer
An assay employing plasma and urine cell-free DNA methylomes is capable of classifying patients across all stages of renal-cell carcinoma, according to preliminary studies.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 2, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma
Percutaneous cryoablation yields survival rates at least as good as those with nephrectomy in patients with stage 1 renal cell carcinoma, according to a prospective observational study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncotarget: Hyperprogression to immune blockade followed by a response with cabozantinib
(Impact Journals LLC) Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2020 Category: Cancer & Oncology Source Type: news

Percutaneous Cryoablation Treats Early-Stage Kidney Cancer
TUESDAY, June 9, 2020 -- Percutaneous cryoablation (PCA) for stage I renal cell carcinoma (RCC) results in good outcomes, with a 10-year disease-specific survival of 94 percent, according to a study published online June 9 in Radiology. John... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2020 Category: Pharmaceuticals Source Type: news

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Source Type: news

Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease –Associated RCC
The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease –associated renal cell carcinoma being treated with the HIF-2a Inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease –Associated Kidney Cancer
The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease –associated renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma
A phase III study presented the 2020 ASCO Virtual Scientific Program showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Novel targeted drug induced positive response for VHL-associated kidney cancer
(University of Texas M. D. Anderson Cancer Center) In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Tivozanib Induces Durable Response Among Patients with Advanced Renal Cell Carcinoma
The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 20, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being cond...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial
The trial evaluated nivolumab in combination with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma, meeting its primary endpoint of progression-free survival at final analysis. (Source: CancerNetwork)
Source: CancerNetwork - April 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Renal Cell Cancer
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 15, 2020 Category: General Medicine Source Type: news

AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 31, 2020-- AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 31, 2020 Category: Drugs & Pharmacology Source Type: news

Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
AKI promotes the development of papillary renal cell carcinoma from single progenitors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 26, 2020 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pathology, Journal, Source Type: news

Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
THURSDAY, March 26, 2020 -- Acute kidney injury (AKI) seems to promote the development of papillary renal cell carcinoma (pRCC) from single progenitors, according to a study published in the March 25 issue of Science Translational Medicine. Anna... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 26, 2020 Category: Pharmaceuticals Source Type: news

Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCC
The findings reported in this study demonstrated a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma and established PT2385 as a highly specific HIF-2 inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Clinical trial exposes deadly kidney cancer's Achilles' heel
(UT Southwestern Medical Center) An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2020 Category: Cancer & Oncology Source Type: news

' Incredible' Results With Kidney Cancer Agent With Nobel Ties'Incredible' Results With Kidney Cancer Agent With Nobel Ties
Once thought to be"undruggable," a target in renal cell carcinoma now has a drug aimed at it, and initial results from a small clinical trial are promising.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novel targeted drug shows promise in advanced kidney cancer
(Dana-Farber Cancer Institute) Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news

Adding Ilixadencel Improved Outcomes in Metastatic RCC Adding Ilixadencel Improved Outcomes in Metastatic RCC
Combining intratumoral injections of ilixadencel with sunitinib improved responses in patients with newly diagnosed synchronous metastatic renal cell carcinoma in the phase 2 MERECA trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Renal Function Change Found to be a Prognostic Factor for Cancer Specific Survival in RCC
The aim of this Chinese study was to evaluate the influencing factors of perioperative renal function change and their relationship with prognosis in patients with renal cell carcinoma and tumor thrombus after nephrectomy and thrombectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

SIR highlights use of percutaneous ablation for RCC
Some patients with renal cell carcinoma (RCC) can be effectively treated nonsurgically...Read more on AuntMinnie.comRelated Reading: SIR aims for more awareness of interventional radiology SIR taps Findeiss as new president SIR: Virtual reality beats fluoroscopy for catheter placement SIR: 'OK, Google -- scrub up!' SIR: Stroke treatment training program improves outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 5, 2020 Category: Radiology Source Type: news

Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After Surgery Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After Surgery
The risk of recurrence in surgically treated renal-cell carcinoma (RCC) persists beyond five years after surgery, suggesting the need for continued surveillance, according to a new analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2019 Category: Consumer Health News Tags: Urology News Source Type: news

Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
Progression - free survival longer in those receiving tivozanib as third - or fourth - line therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 23, 2019 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news

Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
MONDAY, Dec. 23, 2019 -- Among patients with metastatic renal cell carcinoma, progression-free survival was longer in those receiving tivozanib versus sorafenib as third- or fourth-line therapy, according to a study published online Dec. 3 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 23, 2019 Category: Pharmaceuticals Source Type: news

FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma
On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck& Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Study: Mesothelioma Patients with CD70 Protein Have Worse Prognosis
An international team of pathologists has identified a new protein often found on pleural mesothelioma tumor cells. The discovery could lead to a more accurate prognosis for patients and future treatment advances. Researchers found for the first time that mesothelioma patients expressing higher levels of the CD70 protein typically experience a much shorter survival, regardless of cell type or treatment type. “These markers might be useful for MPM [malignant pleural mesothelioma] prognostic evaluations, as well as targeted therapeutics,” the study authors wrote. “Further analyses in syngeneic mouse models...
Source: Asbestos and Mesothelioma News - December 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart
(City of Hope) Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the FDA, reports a City of Hope-led study. Published in The Lancet Oncology, the study is the first to show the benefit of tivozanib for patients with renal cell carcinoma (kidney cancer) who had received two or more previous therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2019 Category: Cancer & Oncology Source Type: news

Renal Cancer Research by Sengenics and the University of Leeds Awarded...
This collaboration will focus on discovery of novel biomarkers for renal cell carcinoma (RCC), with the goal of developing an autoantibody-based early diagnostic test for this disease(PRWeb November 26, 2019)Read the full story at https://www.prweb.com/releases/renal_cancer_research_by_sengenics_and_the_university_of_leeds_awarded_early_detection_primer_grant_funding_from_cancer_research_uk/prweb16740467.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 26, 2019 Category: Pharmaceuticals Source Type: news

Lenvatinib, Pembrolizumab Combo Shows Promising Results in Metastatic RCC
Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - November 5, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

AVEO Oncology Announces Regulatory Update For Tivozanib In Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2019-- AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 4, 2019 Category: Drugs & Pharmacology Source Type: news

Renal Cell Carcinoma: 5 Things to Know Renal Cell Carcinoma: 5 Things to Know
What you need to know about the latest data on treating this common cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Pediatric Renal Cell Carcinoma Pediatric Renal Cell Carcinoma
What knowledge have we gained regarding the presentation and management of renal cell carcinoma in young patients?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
Inactivation of the VHL tumor suppressor gene is the signature initiating event in clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, and causes the accumulation of hypoxia-inducible factor 2α (HIF-2α). HIF-2α inhibitors are effective in some ccRCC cases, but both de novo and acquired resistance have been observed in the laboratory and in the clinic. Here, we identified synthetic lethality between decreased activity of cyclin-dependent kinases 4 and 6 (CDK4/6) and VHL inactivation in two species (human and Drosophila) and across diverse human ccRCC cell lines in culture and xe...
Source: Signal Transduction Knowledge Environment - October 1, 2019 Category: Science Authors: Nicholson, H. E., Tariq, Z., Housden, B. E., Jennings, R. B., Stransky, L. A., Perrimon, N., Signoretti, S., Kaelin, W. G. Tags: STKE Research Articles Source Type: news

Assessing costs of sunitinib treatment in renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2019 Category: Drugs & Pharmacology Source Type: news

The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
A total of $1.3 million awarded to advance new treatments for kidney cancerHOUSTON– September 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA). In April, the KCA approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. “The KCA was delighted by the high caliber of proposals received for both awards and are hopeful that this research will advance the medical community’s understanding of kidney cancer,” said Dr. Christopher Wood, Ch...
Source: Kidney Cancer Association - September 16, 2019 Category: Urology & Nephrology Source Type: news

Aveo CEO says new data eases concerns about troubled kidney cancer drug
Cambridge drugmaker Aveo Oncology is trying again with its kidney cancer drug tivozanib, disclosing new late-stage data Tuesday that sent its stock price shooting up more than 40 percent and adding $60 million to the troubled company ’s market cap.  Tivozanib was developed to treat advanced renal cell carcinoma, the most common form of kidney cancer. But Aveo has been keeping tivozanib on life support since the FDA rejected it back in 2013 due to a higher risk of death or toxicity than the industry’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 10, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer
Nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to an extended follow-up of the ongoing CheckMate 214 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 3, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

A Lesson in Screening For Hereditary Kidney Cancer Syndromes A Lesson in Screening For Hereditary Kidney Cancer Syndromes
This case of a renal cell carcinoma in a 30-year-old highlights the need for screening for hereditary kidney cancer syndromes in patients diagnosed with RCC at a young age.Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2019 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

Setbacks and Advances in Renal Cell Carcinoma Treatment Setbacks and Advances in Renal Cell Carcinoma Treatment
Although we have more evidence against tyrosine kinase inhibitors in the adjuvant setting, studies on immunotherapy and surveillance point toward progress.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 13, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Favorable five-year survival reported for patients with advanced cancer treated with the immunotherapy
(Johns Hopkins Medicine) A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the immunotherapy drug nivolumab (anti-PD-1) as a treatment for patients whose previous therapies failed to stem their advanced melanoma, renal cell carcinoma (RCC) or non-small-cell lung cancer (NSCLC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2019 Category: International Medicine & Public Health Source Type: news

Targeted Therapy Proves Its Worth in Metastatic Kidney Cancer Patients
A new study looked at targeted vs nontargeted therapy in real world patients with renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Nivolumab Trial Failure Raises the Question of Brain Imaging in Kidney Cancer
Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results. (Source: CancerNetwork)
Source: CancerNetwork - July 8, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Pembrolizumab/axitinib too costly in advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2019 Category: Drugs & Pharmacology Source Type: news

Targeted Therapies Linked to Survival Benefits for Older Patients With Advanced Renal Cancer Targeted Therapies Linked to Survival Benefits for Older Patients With Advanced Renal Cancer
Targeted therapies were associated with"modest survival advantages" in elderly Medicare patients with metastatic renal cell carcinoma (mRCC) in a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study Reveals Lower Predictive Ability for Renal Cancer Models
FRIDAY, June 21, 2019 -- Prospective validation of existing renal cell carcinoma (RCC) prediction models demonstrates a decrease in their predictive ability, according to a study published online June 19 in the Journal of Clinical Oncology. Andres... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2019 Category: Pharmaceuticals Source Type: news